2SPD-005 Economical analysis of tenofovir alafenamide versus tenofovir-disoproxil fumarate

• Published in: European journal of hospital pharmacy. Science and practice Vol. 26; no. Suppl 1; p. A21
• Main Authors: Camean-Castillo, M, Rios-Sanchez, E, Gil-Sierra, MD, Briceño-Casado, MP, Salmeron-Navas, FJ, Fenix-Caballero, S, Diaz-Navarro, J, Martinez-Diaz, C, Alegre-Del Rey, EJ, Borrero-Rubio, JM
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.03.2019
• Subjects: Antiretroviral drugs; Patients; Public health
• ISSN: 2047-9956; 2047-9964
• DOI: 10.1136/ejhpharm-2019-eahpconf.45

BackgroundDue to the recent commercialisation of the presentations of Tenofovir Alafenamide (TAF) for HIV, there is a need to analyse the costs involved in its introduction into the public health system and its potential impact.PurposeThe objective of the study is to assess the cost of using TAF instead of tenofovir-disoproxil fumarate (TDF) in a public health hospital.Material and methodsA retrospective and descriptive study of all the patients who used TDF in their HIV treatment regimens from January 2018 to October 2018 was done. Data of the different treatment regimens for HIV containing TDF and adherence to treatment were collected. The TDF treatments regimens were replaced by their commercial equivalent with TAF and the hospital acquisition prices were compared. The cost for each patient was calculated according to TDF or TAF presentation and extrapolated to one year of treatment. The sources of information were the outpatient database and management of the hospital pharmacy service.ResultsDuring the study period, 204 patients used TDF in their treatment regimen for HIV: 151 patients used TDF +emtricitabine + elvitegravir, 16 patients used TDF +emtricitabine + darunavir/cobicistat and 37 used TDF +emtricitabine + another third drug. The adherence to the treatment was 95%. The patient cost and its annual potential cost are summarised in the following table 1:Abstract 2SPD-005 Table 1 N° patients Patient cost Annual cost Difference TDF+emtricitabine+elvitegravir151€560,22€1,015,118.64TAF+emtricitabine+elvitegravir151€726€1,315,512€300,393.36TDF+emtricitabine+darunavir/cobicistat16€380,65€73,084.8TAF+emtricitabine+darunavir/cobicistat16€918€1 76 256€103,171.2TDF+emtricitabine+3° fármaco (not study)37€31.2€13,852.8TAF+emtricitabine+3° fármaco (not study)37€314.3€139.549.2€125,696.4ConclusionAlmost 75% of patients with TDF used a treatment regimen with emtricitabine +elvitegravir. Adherence to the treatment was excellent. The consideration to switch TDF to TAF must take into account its associated cost due to the high impact that would imply.References and/or acknowledgementsNo conflict of interest.